Summary of medicine characteristics - CLOBETASOL PROPIONATE/NEOMYCIN SULPHATE/NYSTATIN 0.5 MG / 5 MG / 100 000 IU/G CREAM, DERMOVATE-NN CREAM
Dermovate-NN Cream
Clobetasol propionate/neomycin sulphate/nystatin 0.5mg/5mg/100,000 IU/g Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram of cream contains clobetasol propionate 0.05% w/w, neomycin sulphate 0.5% w/w and nystatin 100,000 IU.
Excipient(s) with known effect:
This medicine contains arachis oil.
For the full list of excipients, see section 6.1.
Cream.
A smooth buff coloured cream.
4.1 Therapeutic indications
Clobetasol propionate is a highly active topical corticosteroid which is of particular value when used in short courses for the treatment of recalcitrant eczemas, neurodermatoses, and other conditions which do not respond satisfactorily to less active steroids.
Clobetasol/neomycin/nystatin Cream is indicated in more resistant dermatoses such as recalcitrant eczemas and psoriasis (excluding widespread plaque psoriasis) where secondary bacterial or candidal infection is present, suspected or likely to occur, as when using occlusive dressings.
4.2 Posology and method of administration
Clobetasol propionate belongs to the most potent class of topical corticosteroids (Group IV) and prolonged use may result in serious undesirable effects (see section 4.4). If treatment with a local corticosteroid is clinically justified beyond 4 weeks, a less potent corticosteroid preparation should be considered. Repeated but short courses of clobetasol propionate may be used to control exacerbations (see details below).
Posology:
Adults and adolescents
Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations therapy should be discontinued when control is achieved. In the more responsive conditions this may be within a few days.
In very resistant lesions, especially where there is hyperkeratosis, the antiinflammatory effects of Clobetasol/neomycin/nystatin Cream can be enhanced, if necessary, by occluding the treatment area with polythene. Overnight occlusion only is usually adequate to bring about a satisfactory response, thereafter improvement can be usually maintained by application without occlusion.
Treatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient’s condition being reviewed.
Repeat short courses of Clobetasol/neomycin/nystatin Cream may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used.
The maximum weekly dose should not exceed 50 g/week.
Dosage in Renal Impairment
Dosage should be reduced in patients with reduced renal function (see section 4.4).
Elderly
Clobetasol/neomycin/nystatin Cream is suitable for use in the elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of neomycin sulphate may occur (see section 4.4). The minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Paediatric population
Clobetasol/neomycin/nystatin Cream is suitable for use in children (2 years and over) at the same dose as adults. A course of treatment for a child should be limited to 5 days and occlusion should not be used. It should be noted that the child’s napkin may act as an occlusive dressing. A possibility of increased absorption exists in very young children; thus, this cream is not recommended for use in neonates and infants (younger than 2 years) (see sections 4.3 and 4.4).
Care should be taken when using clobetasol propionate with neomycin sulphate and nystatin to ensure the amount applied is the minimum that provides therapeutic benefit.
Method of administration:
For cutaneous use.
4.3 Contraindications
Hypersensitivity to the active substances (clobetasol propionate, neomycin sulphate and nystatin), to arachis oil (peanut oil) or any of the excipients listed in section 6.1 (see sections 4.4 and 4.8).
Rosacea, acne vulgaris and perioral dermatitis.
Primary cutaneous viral infections (e.g. herpes simplex, chickenpox).
Pruritus without inflammation.
Use of Clobetasol/neomycin/nystatin skin preparations is not indicated in the treatment of primary infected skin lesions caused by infection with fungi (e.g. candidiasis, tinea), bacteria (e.g. impetigo), or yeast; secondary infections due to Pseudomonas or Proteus species; perianal and genital pruritus, dermatoses in children under 2 years of age, including dermatitis and napkin eruptions.
Preparations containing neomycin should not be used for the treatment of otitis externa when the eardrum is perforated, because of the risk of ototoxicity.
Due to the known ototoxic and nephrotoxic potential of neomycin sulphate the use of this medicinal product in large quantities or on large areas for prolonged periods is not recommended in circumstances where significant systemic absorption may occur.
A possibility of increased absorption exists in very young children; therefore Clobetasol/neomycin/nystatin Cream is not recommended for use in neonates and infants (up to 2 years). In neonates and infants, absorption by immature skin may be enhanced, and renal function may be immature.
4.4 Special warnings and precautions for use
Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use.
Although this is less likely to occur with topically applied neomycin, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
Manifestations of hypercortisolism (Cushing’s syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression can occur in some individuals as a result of increased systemic absorption of topical corticosteroids.
If either the above is observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency (see section 4.8).
Risk factors for increased corticosteroidal systemic effects are:
Potency and formulation of topical corticosteroid
Duration of exposure
Application to a large surface area
Use on occluded areas of skin e.g. on intertriginous areas or under occlusive dressings (nappies may act as an occlusive dressing)
Increasing hydration of the stratum corneum
Use on thin skin areas such as the face
Use on broken skin or other conditions where the skin barrier may be
impaired
Local hypersensitivity reactions may resemble symptoms of the condition under treatment (see section 4.8). If signs of hypersensitivity appear, application should be stopped immediately.
In comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic adverse effects. This is because children have an immature skin barrier and a greater surface area to bodyweight ratio compared with adults.
Long term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion.
If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. It should be noted that the child’s napkin may act as an occlusive dressing.
Application to the face is undesirable as, more than other areas of the body, this area may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. If used on the face, treatment should be limited to only a few days. This must be borne in mind when treating such conditions as psoriasis and severe eczema.
Long term continuous or inappropriate use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated. Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be with caution and specialist advise is recommended in these cases or other treatment options should be considered.
If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure (see section 4.8). If the cream does enter the eye, it should be bathed in copious amounts of water.
Topical corticosteroids may be hazardous in psoriasis for a number of reasons, including rebound relapses, development of tolerance, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis careful patient supervision is important.
Cases of osteonecrosis serious infections (including necrotizing fasciitis) and systemic immunosuppression (sometimes resulting in reversible Kaposi’s sarcoma lesions) have been reported with long-term use of clobetasol propionate beyond the recommended doses (see section 4.2). In some cases patients used concomitantly other potent oral/topical corticosteroids or immunosuppressors (e.g. methotrexate, mycophenolate mofetil). If treatment with local corticosteroids is clinically justified beyond 4 weeks, a less potent corticosteroid preparation should be considered.
Extension of the infection may occur due to the masking effect of the steroid.
If infection persists, systemic chemotherapy is required. Any spread of infection requires withdrawal of topical corticosteroid therapy.
Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings, and the skin should be cleansed before a fresh dressing is applied.
Following significant systemic absorption, aminoglycosides such as neomycin can cause irreversible ototoxicity; and neomycin has nephrotoxic potential (see section 4.3).
In renal impairment, the plasma clearance of neomycin is reduced (see section 4.2).
Extended or recurrent application may increase the risk of contact sensitization.
Products which contain antimicrobial agents should not be diluted.
Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection.
Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
Arachis oil: Clobetasol/neomycin/nystatin Cream contains arachis oil (peanut oil) and should not be taken/applied by patients known to be allergic to peanuts. As there is a possible relationship between allergy to peanut and allergy to soya, patients with soya allergy should also avoid this medicinal product.
4.5 Interaction with other medicinal products and other forms of interaction
CYP3A4 inhibitors
Co-administered drugs that can inhibit CYP3A4 (e.g. ritonavir and itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor.
Systemic aminoglycoside therapy
Possibility of cumulative toxicity should be considered when neomycin sulphate is applied topically in combination with systemic aminoglycoside therapy.
Neuromuscular blocking agents
Following significant systemic absorption neomycin sulphate can intensify and prolong the respiratory depressant effects of neuromuscular blocking agents. However, if used in accordance with the recommendations systemic exposure to neomycin sulphate is expected to be minimal and drug interactions are unlikely to be significant.
No hazardous interactions have been reported with use of clobetasol propionate or nystatin.
4.6 Fertility, pregnancy and lactation
Pregnancy
There are limited data from the use of clobetasol propionate with neomycin sulphate and nystatin in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see section 5.3). The relevance of this finding to humans has not been established.
Breast-feeding
The safe use of clobetasol propionate with neomycin sulphate and nystatin during breastfeeding has not been established. It is not known whether the topical administration of corticosteroids could result in sufficient systemic absorption to product detectable amounts in breast milk. Thus, the use of clobetasol propionate with neomycin sulphate and nystatin is not recommended in lactation.
Fertility
There are no data in humans to evaluate the effect of topical clobetasol propionate with neomycin sulphate and nystatin on fertility.
Clobetasol propionate administered subcutaneously to rats had no effect upon mating performance; however, fertility was decreased at the highest dose (see section 5.3). The relevant of this finding to humans has not been established.
4.7 Effects on ability to drive and use machines
Clobetasol/neomycin/nystatin Cream has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: Very common (> 1/10); common (> 1/100 to <1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Clinical trial data
| Skin and subcutaneous tissue disorders | |
| Common: | Skin atrophy*, telangiectasis* |
| Uncommon: | Striae |
Skin features related to hypothalamic-pituitary adrenal (HPA) axis suppression.
Post-marketing data
| Infections and infestations | |
| Very rare: | | Opportunistic infection |
| Immune system disorders | |
| Very rare: | Allergic reactions including anaphylaxis and hypersensitivity |
| Endocrine disorders | |
| Very rare: | Hypothalamic-pituitary adrenal (HPA) axis suppression: Cushingoid features (e.g. moon face, central obesity), delayed weight gain/growth retardation in children, osteoporosis, glaucoma, hyperglycaemia/glucosuria, cataract, hypertension, increased weight/obesity, decreased endogenous cortisol levels |
| Skin and subcutaneous tissue disorders | |
| Very rare: | Skin thinning*, skin wrinkling*, skin dryness*, pigmentation changes*, hypertrichosis, exacerbation of underlying symptoms, allergic contact |
| dermatitis/dermatitis, pustular psoriasis (see section 4.4), erythema, rash, urticaria, alopecia*, trichorrhexis*, pruritus, local skin burning/skin pain | |
| Not known: | Withdrawal reactions – redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules. (see section 4.4) |
| *Skin features related to hypothalamic-pituitary adrenal (HPA) axis suppression. | |
| General disorders and administration site conditions | |
| Very rare: | Application site irritation/pain |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Symptoms and signs
Topically applied clobetasol propionate may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may appear (see section 4.4 and 4.8).
Treatment
In the event of chronic overdosage or misuse topical steroids should be withdrawn gradually under medical supervision by reducing the frequency of application or by substituting a less potent corticosteroid because of the risk of adrenal insufficiency.
Consideration should be given to significant systemic absorption of neomycin sulphate (see section 4.4 and 4.5). If this is suspected, use of the product should be stopped and the patient’s general status, hearing acuity, renal and neuromuscular functions should be monitored.
Blood levels of neomycin sulphate should also be determined. Haemodialysis may reduce the serum level of neomycin sulphate.
Further management should be as clinically indicated or as recommended by the National Poisons Centre, where available
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacoterapeutic group: Clobetasol and antibiotics, ATC code: D07CD01
Mechanism of action
Clobetasol propionate is a highly active corticosteroid with topical anti-inflammatory activity. The major effect of clobetasol propionate on skin is a non-specific anti-inflammatory response, partially due to vasoconstriction and decrease in collagen synthesis.
The use of nystatin in the local treatment of candidal infections of the skin and of neomycin as a broad-spectrum antibiotic is well known.
The principle action of the preparation is based on the anti-inflammatory activity of the corticosteroid. The broad spectrum antibacterial and anti-candidal activity provided by the combination of neomycin and nystatin allow this effect to be utilised in the treatment of condition which are likely to become infected.
5.2 Pharmacokinetic properties
Absorption
Percutaneous penetration of clobetasol propionate varies among individuals and can be increased by the use of occlusive dressings, or when the skin is inflamed or diseased.
Distribution
Mean peak plasma clobetasol propionate concentrations of 0.63ng/ml occurred in one study 8 hours after the second application (13 hours after an initial application) of 30g clobetasol propionate 0.05% ointment to normal individuals with healthy skin. Following the application of a second dose of 30g of clobetasol propionate cream 0.05% mean peak plasma concentrations were slightly higher than the ointment and occurred 10 hours after application.
Biotransformation
In a separate study, mean peak plasma concentrations of approximately 2.3ng/ml and 4.6ng/ml occurred respectively in patients with psoriasis and eczema 3 hours after a single application of 25g clobetasol propionate 0.05% ointment. However, systemic metabolism of clobetasol has never been fully characterised or quantified. Following percutaneous absorption of clobetasol propionate the drug probably follows the metabolic pathway of systemically administered corticosteroids, i.e. metabolised primarily by the liver and then excreted by the kidneys.
5.3 Preclinical safety data
In fertility studies, subcutaneous administration of clobetasol propionate to rats at doses of 6.25 to 50 micrograms/kg/day produced no effects on mating, and fertility was only decreased at 50 micrograms/kg/day.
Subcutaneous administration of clobetasol propionate to mice (>100 micrograms/kg/day), rats (400 micrograms/kg/day) or rabbits (1 to 10 micrograms/kg/day) during pregnancy produced foetal abnormalities including cleft palate.
In the rat study, where some animals were allowed to litter, developmental delay was observed in the F1 generation at >100 micrograms/kg/day and survival was reduced at 400 micrograms/kg/day. No treatment-related effects were observed in F1 reproductive performance or in the F2 generation.
6.1 List of excipients
Microcrystalline wax
Arachis oil
Polyoxyethylene cetyl ether
White beeswax or beeswax substitute 6621
Titanium dioxide (E 171)
Propyl gallate
Ultra light liquid paraffin.
6.2 Incompatibilities
None known
6.3 Shelf life
36 months
6.4 Special precautions for storage
Store below 25°C
6.5 Nature and contents of container
Collapsible aluminium tube, with a polypropylene cap.
Pack sizes: 25g or 30g
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Do not dilute.
Patients should be advised to wash their hands after applying
Clobetasol/neomycin/nystatin Cream unless it is the hands that are being treated.
7 MARKETING AUTHORISATION HOLDER
Chemidex Pharma Limited
Chemidex House
Unit 7, Egham Business Village
Crabtree Road
Egham
Surrey
TW20 8RB
United Kingdom
8 MARKETING AUTHORISATION NUMBER
PL 17736/0100
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THEAUTHORISATION
11 December 1995